ArticleCureus2025
Assessing Alloimmunization in Sickle Cell Disease Patients: Insights From a Tertiary Care Center Study on Multiple Blood Transfusion Recipients in Central India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlloimmunization is defined as a delayed transfusion reaction, which occurs days to months after transfusion, in which a patient may produce antibodies against a red cell antigen that the patient lacks. This alloimmunization process is influenced by genetic as well as acquired patient-related factors. This study aims to determine the pattern and frequency of allo-antibodies in patients with sickle cell disease (SCD) who have undergone multiple transfusions. MATERIAL AND
methodsWe carried out a prospective observational study at a tertiary care hospital in central India. Our focus was on patients with SCD who received multiple blood transfusions to assess their alloimmunization status by using Panoscreen® I, II, and III (Immucor, Inc., Norcross, GA) and PANOCELL 16 (Immucor, Inc.) antibody identification panel.
resultsAmong 140 samples screened, five (3.57%) tested positive for antibodies. Of these, two (1.42%) had autoantibodies and three (2.15%) had alloantibodies. The prevalence of alloimmunization was not statistically significant (p = 0.418, 95% CI).
conclusionAlloantibodies detected were predominantly against the Rh system and not clinically significant. However, the findings highlight the need for enhanced immunohematologic testing to prevent alloimmunization and improve transfusion care in SCD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.